The global gelatin polypeptide plasma expanders market was valued at USD 254.95 million in 2022. It is expected to reach USD 341.47 million by 2031, growing at a CAGR of 3.3% during the forecast period (2023–2031).
Plasma expander, also known as plasma compatibilizer, is a plasma substitute. The global market for gelatin polypeptide plasma volume enhancers is highly concentrated. Plasma expanders are currently available in two types: colloid and crystalloid. It can be used as an alternative to dextran, albumin, and other colloidal expanders.
Volume expanders are extensively used in orthopedic, hepatic, and vascular surgeries daily. It is also used in an emergency or critical situation involving blood loss. According to CDC, in 2018, 35 million injury-related emergency care patients were admitted in the US. Thus, increasing the demand for plasma expanders and driving the market growth.
Due to the high quantity of endotoxin, the therapeutic use of gelatin plasma expanders for hypovolemic shocks and other conditions involving blood loss is limited. However, significant efforts are being made to reduce the level of endotoxin in the foundation ingredient, gelatin. These efforts can drive the market to high growth.
The increased use of plasma expanders has been a significant market driver. The new generation gelatin expanders, Gelofusine and Haemaccel, are widely utilized in the United Kingdom. According to the Royal College of Anesthetists' 6th National Audit Project (NAP6), gelatin-based products were the most commonly used colloid (i.e., 1.7% of all fluid administrations), followed by starch or starch-based products (0.2%) and albumin (0.1%). NAP6 enlisted the participation of all NHS hospitals.
The market is divided into three segments based on application: perioperative, extracorporeal circulation, and dialysis. Perioperative had the largest market share, amounting to USD 134.6 million in 2018 due to a high number of surgeries and subsequent blood loss, mandating the use of plasma expanders to maintain plasma volume. Porcine gelatin, essentially made from pigskin, is the leading source of gelatin. It is preferred as it is cheaper and hence produces a huge market revenue.
The emergence of the COVID-19 pandemic prompted the imposition of strict lockdown in most countries, causing delays in the import and export of gelatin-based plasma expanders. COVID-19 has the potential to impact the global economy in three ways, i.e., directly affecting production and demand, causing supply chain and market disruption, and facing a financial impact on businesses and financial markets.
North America dominates the market. An intravenous volume expander is used in treating blood diseases, blood loss, hypovolemia, pancreatitis, and trauma. The treatment aids people injured in a severe accident. The number of road accidents is increasing at an alarming rate in North America, and many of these incidents are caused by drunk driving. These accidents result in injuries, life-long impairment, or death, depending on their severity. In the United States, 12 million vehicles were involved in accidents in 2018.
Over 4.4 billion people live in Asia-Pacific. The region provides reasonably decent healthcare at a low cost and bears the brunt of the global disease burden. Cancer, heart diseases, diabetes, and COPD affect Japan, Australia, and South Korea. Many countries in Asia-Pacific have boosted their healthcare spending to provide better healthcare services.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
September 2021- Abbott, a global healthcare firm, released the Amplatzer PiccoloTM Occluder in India, the world's first medical device for treating patent ductus arteriosus (PDA). It can be implanted in the youngest neonates (weighing as little as 700 gms) via a minimally invasive process.
March 2021- Piramal Pharma Limited’s (PPL) Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions (PPS), announced that PPL has agreed to acquire a 100% stake in Hemmo Pharmaceuticals Pvt. Ltd. (Hemmo).